Laurie Pukac

2.8k total citations
21 papers, 1.4k citations indexed

About

Laurie Pukac is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Laurie Pukac has authored 21 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Genetics. Recurrent topics in Laurie Pukac's work include Neutropenia and Cancer Infections (5 papers), Angiogenesis and VEGF in Cancer (4 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Laurie Pukac is often cited by papers focused on Neutropenia and Cancer Infections (5 papers), Angiogenesis and VEGF in Cancer (4 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Laurie Pukac collaborates with scholars based in United States, Israel and Germany. Laurie Pukac's co-authors include Morris J. Karnovsky, Qinghai Zhao, Michael E. Ottlinger, M J Karnovsky, Maarten van Dinther, Peter ten Dijke, Marion Scharpfenecker, Zhen Liu, Clemens W.G.M. Löwik and R.L. van Bezooijen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Laurie Pukac

21 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laurie Pukac United States 14 840 231 200 185 166 21 1.4k
Emanuela Moroni Italy 16 1.4k 1.6× 293 1.3× 188 0.9× 331 1.8× 98 0.6× 20 2.1k
Sophia K. Khaldoyanidi United States 24 788 0.9× 314 1.4× 144 0.7× 151 0.8× 125 0.8× 50 1.7k
Yoshiya Shimao Japan 15 508 0.6× 255 1.1× 168 0.8× 246 1.3× 166 1.0× 43 1.2k
Jacques Hatzfeld France 26 1.1k 1.3× 165 0.7× 188 0.9× 186 1.0× 135 0.8× 63 1.9k
B Nico Italy 16 899 1.1× 140 0.6× 98 0.5× 213 1.2× 96 0.6× 22 1.5k
Antoinette Hatzfeld France 27 1.1k 1.3× 173 0.7× 205 1.0× 207 1.1× 141 0.8× 74 2.2k
Graziano Seghezzi United States 9 900 1.1× 134 0.6× 112 0.6× 450 2.4× 156 0.9× 11 1.4k
Pedro Lastres Spain 20 844 1.0× 90 0.4× 383 1.9× 207 1.1× 223 1.3× 27 1.6k
Hiroyuki Sugahara Japan 16 681 0.8× 141 0.6× 186 0.9× 76 0.4× 285 1.7× 36 1.9k
Suzanne Spong United States 11 729 0.9× 189 0.8× 187 0.9× 204 1.1× 194 1.2× 12 1.4k

Countries citing papers authored by Laurie Pukac

Since Specialization
Citations

This map shows the geographic impact of Laurie Pukac's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurie Pukac with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurie Pukac more than expected).

Fields of papers citing papers by Laurie Pukac

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurie Pukac. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurie Pukac. The network helps show where Laurie Pukac may publish in the future.

Co-authorship network of co-authors of Laurie Pukac

This figure shows the co-authorship network connecting the top 25 collaborators of Laurie Pukac. A scholar is included among the top collaborators of Laurie Pukac based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurie Pukac. Laurie Pukac is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liddament, Mark T., et al.. (2019). Higher Binding Affinity and In Vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab. Allergy Asthma and Immunology Research. 11(2). 291–291. 14 indexed citations
2.
Zou, Linglong, Laurie Pukac, Yael Shalit, et al.. (2018). Immunogenicity assessment of intravenous administration of reslizumab in patients with asthma in phase 3 clinical studies. PA1032–PA1032. 3 indexed citations
3.
Avisar, Noa, et al.. (2015). First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. Cancer Chemotherapy and Pharmacology. 75(5). 929–939. 4 indexed citations
4.
Kaufman, Thomas M., Philip A. Krasney, Laurie Pukac, et al.. (2015). Differential sensitivity of lipegfilgrastim and pegfilgrastim to neutrophil elastase correlates with differences in clinical pharmacokinetic profile. The Journal of Clinical Pharmacology. 56(2). 186–194. 10 indexed citations
5.
Pukac, Laurie, Philip A. Krasney, Hermann Allgaier, et al.. (2013). Pegylated Versus Glycopegylated G-CSFs and Their Biochemical and Physiological Properties. Blood. 122(21). 4851–4851. 6 indexed citations
6.
Pukac, Laurie, Steven Barash, Noa Avisar, et al.. (2013). Balugrastim: A long-acting, once-per-cycle, recombinant human albumin-fusion filgrastim.. Journal of Clinical Oncology. 31(15_suppl). e13551–e13551. 2 indexed citations
7.
Avisar, Noa, Laurie Pukac, Steve Barash, et al.. (2013). Recombinant Albumin-Partnering Technology: Development Of Balugrastim, a Novel Long-Acting Granulocyte Colony-Stimulating Factor. Blood. 122(21). 4854–4854. 4 indexed citations
8.
Scharpfenecker, Marion, Maarten van Dinther, Zhen Liu, et al.. (2007). BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. Journal of Cell Science. 120(6). 964–972. 415 indexed citations
9.
Brown, Monica, Qinghai Zhao, Kent A. Baker, et al.. (2005). Crystal Structure of BMP-9 and Functional Interactions with Pro-region and Receptors. Journal of Biological Chemistry. 280(26). 25111–25118. 241 indexed citations
10.
Huang, Xiaofeng, Michele Fiscella, Laurie Pukac, et al.. (2003). Human agonistic anti-TRAIL receptor antibodies, HGS-ETR1 and HGS-ETR2, induce apoptosis in diverse hematological tumor lines. Blood. 102(11). 89116. 5 indexed citations
11.
12.
Pukac, Laurie, et al.. (1997). Enhancement of Diaminobenzidine Colorimetric Signal in Immunoblotting. BioTechniques. 23(3). 385–388. 32 indexed citations
13.
Edelman, Elazer R., Laurie Pukac, & Morris J. Karnovsky. (1993). Protamine and protamine-insulins exacerbate the vascular response to injury.. Journal of Clinical Investigation. 91(5). 2308–2313. 14 indexed citations
14.
Karnovsky, Morris J., et al.. (1993). Isolation of heparin-insensitive aortic smooth muscle cells. Growth and differentiation.. Arteriosclerosis and Thrombosis A Journal of Vascular Biology. 13(5). 748–757. 24 indexed citations
15.
Ottlinger, Michael E., Laurie Pukac, & Morris J. Karnovsky. (1993). Heparin inhibits mitogen-activated protein kinase activation in intact rat vascular smooth muscle cells.. Journal of Biological Chemistry. 268(26). 19173–19176. 92 indexed citations
16.
Pukac, Laurie, Michael E. Ottlinger, & M J Karnovsky. (1992). Heparin suppresses specific second messenger pathways for protooncogene expression in rat vascular smooth muscle cells.. Journal of Biological Chemistry. 267(6). 3707–3711. 94 indexed citations
17.
Pukac, Laurie, Gregory M. Hirsch, J C Lormeau, et al.. (1991). Antiproliferative effects of novel, nonanticoagulant heparin derivatives on vascular smooth muscle cells in vitro and in vivo.. PubMed. 139(6). 1501–9. 36 indexed citations
18.
Pukac, Laurie, John J. Castellot, Thomas C. Wright, Benjamin Caleb, & Morris J. Karnovsky. (1990). Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells.. PubMed. 1(5). 435–443. 116 indexed citations
19.
Pukac, Laurie & Nelson D. Horseman. (1987). Regulation of Cloned Prolactin-Inducible Genes in Pigeon Crop*. Molecular Endocrinology. 1(2). 188–194. 18 indexed citations
20.
Pukac, Laurie & Nelson D. Horseman. (1984). Regulation of Pigeon Crop Gene Expression by Prolactin*. Endocrinology. 114(5). 1718–1724. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emanuela Moroni Breakdown of academic impact, for papers by Sophia K. Khaldoyanidi Breakdown of academic impact, for papers by Yoshiya Shimao Breakdown of academic impact, for papers by Jacques Hatzfeld Breakdown of academic impact, for papers by B Nico Breakdown of academic impact, for papers by Antoinette Hatzfeld Breakdown of academic impact, for papers by Graziano Seghezzi Breakdown of academic impact, for papers by Pedro Lastres Breakdown of academic impact, for papers by Hiroyuki Sugahara Breakdown of academic impact, for papers by Suzanne Spong
Rankless by CCL
2026